EUVIMEDEUVIMED entdecken
Crossref

Lymphocyte recovery after bendamustine therapy in patients with mantle cell lymphoma. Results of a retrospective analysis and prognostic impact in the CAR-T era

Livia Donzelli, M Antonacci, N Zhdanovskaya, L Petrucci, M Di Palma, M Martelli, A Di Rocco

Annals of Hematology · 2024

DOI: 10.1007/s00277-024-05962-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, 2024. Verfasst von Livia Donzelli und 6 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Unit, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy. donzelli@bce.uniroma1.it. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell, Bendamustine Hydrochloride, Immunotherapy, Adoptive. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bendamustine in combination with rituximab (BR) or with rituximab and cytarabine (R-BAC) is the standard first-line immunochemotherapy in mantle cell lymphoma (MCL) for elderly patients and patients ineligible for intensive regimens or autologous transplantation. As bendamustine causes prolonged lymphopenia and the literature lacks evidence of its persistence in patients with MCL, this retrospective analysis aims to estimate the lymphocyte recovery time, also in view of potential immunotherapy with CAR-T cells. Data were collected from 44 consecutive MCL patients who received bendamustine (BR or R-BAC) as first-line therapy at the Hematology Unit of Sapienza University Hospital between May 2011 and April 2022. Twenty patients (45%) were treated with R-BAC and 24 (55%) with BR. At baseline, the median lymphocyte count was 1795/µl (range: 370-11730/µL). One month after the end of therapy, it was 450/µl (range: 50-3300/µl) and 3 months after 768/µl (range: 260-1650/µl). After 6 and 9 months, we observed a gradual increase in median lymphocyte count of 900/µl (range: 370-2560/µl and 130-2770/µl, respectively). After 12 months median lymphocyte count was 1256/µl (range: 240-4140/µl). Median lymphocyte count at 1, 3, 6, and 9 months post-treatment was significantly lower than baseline but showed recovery by the 12 months. This finding is crucial for MCL patients considering CAR-T cell therapy, suggesting a minimum 9-month interval between bendamustine administration and leukapheresis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Mantle-CellBendamustine HydrochlorideImmunotherapy, AdoptiveHumansRetrospective StudiesMaleAgedFemaleMiddle AgedAged, 80 and overLymphocyte CountRituximabAntineoplastic Combined Chemotherapy ProtocolsPrognosisLymphocytesCytarabineAntineoplastic Agents, Alkylating

Stichwörter der Autor:innen

BendamustineCAR T-cell immunotherapyLymphocyte countMantle cell lymphomaNon-hodgkin lymphoma

Substanzen

Bendamustine HydrochlorideRituximabCytarabineAntineoplastic Agents, Alkylating

Autor:innen und Institutionen

  • Hematology Unit, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy. donzelli@bce.uniroma1.it.
  • Hematology Unit, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.
  • Hematology Unit, AORN Sant'Anna e San Sebastiano, Caserta, Italy.

Zitieren

APA

Donzelli, L., Antonacci, M., Zhdanovskaya, N., Petrucci, L., Di Palma, M., Martelli, M., & Di Rocco, A. (2024). Lymphocyte recovery after bendamustine therapy in patients with mantle cell lymphoma. Results of a retrospective analysis and prognostic impact in the CAR-T era. Annals of Hematology. https://doi.org/10.1007/s00277-024-05962-y

Vancouver

Donzelli L, Antonacci M, Zhdanovskaya N, Petrucci L, Di Palma M, Martelli M, et al. Lymphocyte recovery after bendamustine therapy in patients with mantle cell lymphoma. Results of a retrospective analysis and prognostic impact in the CAR-T era. Annals of Hematology. 2024. doi:10.1007/s00277-024-05962-y

BibTeX
@article{Donzelli2024,
  author = {Donzelli, Livia and Antonacci, M and Zhdanovskaya, N and Petrucci, L and Di Palma, M and Martelli, M and Di Rocco, A},
  title = {Lymphocyte recovery after bendamustine therapy in patients with mantle cell lymphoma. Results of a retrospective analysis and prognostic impact in the CAR-T era},
  journal = {Annals of Hematology},
  year = {2024},
  doi = {10.1007/s00277-024-05962-y}
}
Kostenlos starten →